Ficlatuzumab
Ficlatuzumab
Ficlatuzumab (pronounced as fik-la-too-zoo-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a targeted therapy that works by blocking the activity of a specific protein in the body that promotes cancer growth.
Etymology
The name "Ficlatuzumab" is derived from the International Nonproprietary Names (INN), where "-mab" is used for monoclonal antibodies, "tu-" for tumor, "zu-" for humanized, and "ficla-" is a unique stem.
Mechanism of Action
Ficlatuzumab works by targeting and inhibiting the Hepatocyte Growth Factor (HGF)/c-Met pathway, a key process in cancer cell growth and survival. By blocking this pathway, Ficlatuzumab can slow down or stop the growth of cancer cells.
Clinical Trials
Ficlatuzumab is currently in various stages of clinical trials for the treatment of different types of cancer, including head and neck cancer, non-small cell lung cancer, and pancreatic cancer.
Related Terms
External links
- Medical encyclopedia article on Ficlatuzumab
- Wikipedia's article - Ficlatuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski